SEC filings and other documents

Record revenue growth driven by ANKTIVA adoption, but net loss increased on higher non-cash expenses.

All directors re-elected and auditor ratified; results to be filed with the SEC.

ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications.

Q1 2026 revenue jumped 168% year-over-year, but net loss deepened due to non-cash charges.

Global immunotherapy expansion accelerates with durable clinical results and new market launches.

ANKTIVA drives global immunotherapy growth with strong efficacy, approvals, and financial momentum.

Revenue up 700% to $113M, global Anktiva expansion, and net loss narrowed by $62M.

Strong ANKTIVA uptake, global expansion, and pivotal trial progress drive near-term milestones.

Q2 2025 revenue jumped 60% sequentially, with ANKTIVA fueling robust growth and reduced net loss.

Net product revenue more than doubled in Q1 2025, fueled by ANKTIVA's rapid adoption.

Immunotherapy platform delivers durable cancer remissions, expands globally, and targets new indications.

ANKTIVA delivers durable cancer responses, global expansion, and robust pipeline momentum.

J-code approval and FDA actions drive ANKTIVA sales surge and improved financial outlook.

Q3 2024 revenue jumped on ANKTIVA's launch, with global expansion and coverage accelerating.

FDA approval and launch of ANKTIVA mark a pivotal shift, but losses persist.